Počet záznamů: 1
Therapy for minimal residual tumour disease: beta-galactosylceramide inhibits growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy
0333598 - UMG-J 2011 RIV DE eng J - Článek v odborném periodiku
Šímová, Jana - Indrová, Marie - Bieblová, Jana - Mikyšková, Romana - Bubeník, Jan - Reiniš, Milan
Therapy for minimal residual tumour disease: beta-galactosylceramide inhibits growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy.
International Journal of Cancer. Roč. 126, č. 12 (2010), s. 2997-3004 ISSN 0020-7136
Grant CEP: GA ČR GA301/06/0774; GA AV ČR IAA500520807; GA ČR GA301/07/1410; GA ČR GA301/09/1024
GRANT EU: European Commission(XE) 18933 - CLINIGENE
Výzkumný záměr: CEZ:AV0Z50520514
Klíčová slova: beta-galactosylceramide * tumour immunotherapy * NKT cells
Kód oboru RIV: EB - Genetika a molekulární biologie
Impakt faktor: 4.926, rok: 2010
This study was focused on tumour-inhibitory effects of 12 carbon acyl chain beta-galactosylceramide (C12 beta-D-GalactosylCeramide) on the growth of HPV16-associated neoplasms transplanted in syngeneic mice. Treatment of tumour-bearing mice with beta-galactosylceramide 3-14 days after tumour cell transplantation significantly inhibited growth of the MHC class I-positive (TC-1), as well as MHC class I-deficient (TC-1/A9) HPV16-asssociated tumours. Administration of beta-galactosylceramide after surgical removal of TC-1 tumours inhibited growth of tumour recurrences. Similar results were obtained in the treatment of the tumours after chemotherapy. Beta-galactosylceramide treatment turned out to be also synergistic with immunotherapy based on administration of IL-12-producing cellular vaccines. These results suggest that beta-galactosylceramide can be effective for treatment of minimal residual tumour disease as well as an adjuvant for cancer immunotherapy.
Trvalý link: http://hdl.handle.net/11104/0178543
Název souboru Staženo Velikost Komentář Verze Přístup 0333598.pdf 5 380.1 KB Vydavatelský postprint vyžádat